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Rezumat. Rolul medicamentului Meldonium în tratamentul complex al pacienților cu pancreatita cronică 
asociată cu boala coronariană stabilă
Тerapia metabolică este una dintre puținele metode de restabilire a funcției normale a tuturor organelor și sistemelor 
vitale. Scopul studiului a fost de a examina efi cacitatea cursului de tratament medicamentos metabolic cu Vazonat (meldo-
nium dihidrat) pentru corectarea dereglărilor prooxidanț-antioxidante și trophologice la pacienții cu patologie combinată: 
pancreatită cronică (PC) și boala coronariană stabilă (BCS). Studiul a inclus 90 de pacienți cu PC în asociere cu BCS, 
care au fost divizați în 2 grupuri în funcție de tratament: grupul I, 45 pacienți, au primit tratament convențional (TC); gru-
pul II, 45 pacienți, suplimentar a fost administrat Vazonat: 5 ml intravenos, 10 zile, urmat de administrarea unei capsule 
(250mg), de 2 ori pe zi, timp de o lună. S-a demonstrat că adăugarea la tratament a medicamentului Vazonat la pacienții 
cu patologia asociată PC și BCS îmbunătățește indicatorii de stare trophologică și a sistemului antioxidant-prooxidant.
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Summary
Metabolic therapy is one of few ways to recreate normal work of all vital organs and systems. The aim of the work 
was to examine the effi ciency of protracted treatment with metabolic medication Vazonat (meldonium dihydrate) on the 
correction of the prooxidant-antioxidant and trophological violation in patients with comorbide course of chronic pancre-
atitis (CP) and stable coronary artery disease (SCAD). The study included 90 patients with CP and SCAD who were divi-
ded into two groups: I group (45 patients) received standard treatment (ST); II group (45 patients) except ST additionally 
received meldonium according to the following sketch: 5ml intravenously once a day during 10 days with its succeeding 
receiving of 250 mg twice a day in capsules during one month. It was proved that adding meldonium to the complex 
treatment of the patients with CP and SCAD comorbidity greatly assists improving of the indices of trophological and 
prooxidant-antioxidant in comparison with general basic therapy. 
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Резюме. Роль медикамента Мельдоний в комплексном лечении больных хроническим панкреатитом, 
ассоциированным со стабильной ишемической болезнью сердца
Метаболическая терапия – один из немногих способов восстановить нормальную работу всех жизненно важ-
ных органов и систем. Цель исследования состояла в изучении эффективности курса лечения метаболическим 
препаратом Вазонат (дигидрат мелдония) для коррекции прооксидантно-антиоксидантных и трофологических 
нарушений у пациентов с сочетанной патологией: хроническим панкреатитом (ХП) и стабильной ишемической 
болезнью сердца (СИБС). Исследование включало 90 пациентов с ХП в сочетании с СИБС, которые были раз-
делены на две группы в зависимости от программы лечения: I группа (45 пациентов) получила традиционное 
лечение (ТЛ); группа II (45 пациентов), кроме ТЛ, дополнительно получали Вазонит следующим образом: 5мл 
внутривенно болюсно 1 раз в день в течение 10 дней с последующим приемом 1 капсулы (250 мг), 2 раза в день в 
течение одного месяца. Было показано, что дополнение лечения пациентов с ХП в сочетании с СИБС препаратом 
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Вазонат способствует улучшению показателей трофологического статуса и прооксидантно-антиоксидантной си-
стемы, чем стандартная базовая терапия.
Ключевые слова: хронический панкреатит, стабильная ишемическая болезнь сердца, метаболическая тера-
пия, мельдониум, Вазонат
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Background. CP is one of the most common, 
rapidly progressive pancreas diseases (increase up 
to 70.0%) with high cases of temporary incapacity 
to work and primary invalidity (to 15.0%). CP is 
characterized by a progressive course with the 
growing of functional insuffi ciency of the pancreas, 
development of trophological insuffi ciency (TI) 
and abnormalities in the prooxidant-antioxidant 
system [1,2,3]. Such epidemiological data are largely 
derived from the maintenance of the signifi cance of 
the following main etiological factors of CP: alcohol 
abuse, presence of the liver and biliary tract diseases, 
stomach and duodenum diseases, hyperlipidemia 
which is an atherosclerosis component, and also the 
increase of the infl uence of the adverse environmental 
factors [4,5,6].
CP causes imbalance between the intake of 
nutrients in the patient’s body and his need in them. 
Under these conditions TI, which is characterized by 
the syndrome of energy, protein, vitamins, minerals 
and electrolytes defi ciency, especially protein 
defi ciency, secondary immunodefi ciency, osteoporotic 
symptoms, anemia, etc., deepens [7, 8, 9]. In the setting 
of progressive functional insuffi ciency of the pancreas 
and TI enhancement, the reserves of the nutrients in 
tissues run out; this initially leads to biochemical and 
functional changes, and subsequently is manifested 
in numerous and complex clinical symptoms [10,11]. 
The TI development contributes to the CP progression 
as well as its complications. Affected by the formed 
TI, there appears a defi ciency in microelements and 
vitamins, which is an underlying decrease of the 
antioxidant system (AOS) function with CP and lipid 
pre-oxidant (LPO) activation, chronic infl ammatory 
process in the pancreas tissue is potentiated, which 
leads to the progression of fi brosis and atrophy of the 
parenchyma [12,13].
The activation of the LPO with the simultaneous 
development of AOS insuffi ciency occurs in the 
patients with the comorbid course of CP and SCAD. 
Thus, the imbalance in the LPO/AOS system is a 
damaging link in the chain of a metabolic control; 
it affects the formation and the progression of CP. 
Besides, the presence and depth of the disturbances in 
the prooxidant-antioxidant system largely determine 
the severity of the disease. During oxidative stress 
free radicals block metabolism in acinar cells, melt 
lysosome zymogen granules, oxidize lipids of cell 
membranes, thus an infl ammatory reaction with 
mast cells degeneration, platelets and complement 
activation begin, which in turn activates pancreatic 
proenzymes [14,15].
It is known that CP negatively affects cardiovascular 
system. It has been found that 15.5% of patients 
with gastroenterological abnormalities, including 
pancreatitis, have got SCAD. The mechanisms of the 
impact of implementation of infl ammatory process in 
the pancreas on the development and progression of 
SCAD have not been explored suffi ciently so far [16]. 
The combination of CP and SCAD leads to a number 
of structural and metabolic changes that affect the 
course of the both diseases, and causes the necessity 
of the development of a systematic approach to the 
study of the indicated disorders in this group of 
patients [17]. The uncertainty of these mechanisms 
leaves the issue of the drug therapy of such patients 
unsolved, that generally reduces the effectiveness of 
the treatment of the patients suffering from SCAD. 
Therefore, the search for effective treatment regimens 
in this area is essential for modern medicine [18, 19].
The standard basic comorbidity therapy of CP and 
SCAD does not include correction of trophological 
and prooxidant-antioxidant disorders [20]. The 
prescription of metabolic drugs has become common 
in medical practice in the recent years. Vazonat, 
‘Onlinefarm’, Latvia, (meldonium dehydrate) is 
one of the most affordable and the main high-tech 
metabolic cytoprotector. Vazonat belongs to the 
partial fatty acid oxidation inhibitors. The mechanism 
of meldonium action is linked to the return limit of 
speed of biosynthesis of carnitine with its predecessor 
– gramma-butyrobetaine. Consequently, carnitine 
mediated transport of long-chain fatty acids across 
mitochondrial membranes, without affecting the 
metabolism of short-fatty acids, slows down, that 
is why Vazonat is able to infl uence the changes in 
trophological and prooxidant-antioxidant statues.
So, the use of metabolic drugs in a standard basic 
treatment of comorbidity CP and SCAD is the most 
appropriate and pathogenically reasonable.
The purpose of the research was to investigate 
the effectiveness of a course of treatment with 
metabolic drug Vazonat (meldonium dihydrate) 
to the correction of trophological and prooxidant-
antioxidant disorders in the patients with comorbid 
course of CP and SCAD.
Materials and methods. In order to achieve our 
aim, we selected 90 patients with CP concomitant 
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with SCAD (I-II functional classes of angina of 
pectoris), who were treated at the day patient 
department at Ternopil City Municipal Hospital № 2. 
The groups consisted of 46 men (51.2 %), the overall 
average age – (49.9±8,7) years old and 44 women 
(48.8 %), the overall average age – (52.65±6.2) years 
old. The study did not include patients with acute 
forms of IHD in amnesia, insulin-dependent diabetes, 
unstable angina, severe hypertension, severe cardiac 
arrhythmias and severe comorbidities.
Depending on the treatment programs for 
patients, they were divided into two groups; I group 
(45 patients) received the standard treatment (ST) 
(nitrates, beta-blockers, angiotensin-converting 
enzyme inhibitors, angiotensin receptor antagonists 
II, calcium channel blockers, statins, antiaggregants, 
antispasmodics, prokinetics, proton pump inhibitors, 
enzyme preparations); II group (45 patients) except 
for ST received additional drug Vazonat (meldonium 
dihydrate) as follows: 5 ml intravenous bolus 
injection once a day for 10 days followed by 1 
capsule (250 mg), two times per day for one month. 
The control group consisted of 20 healthy individuals 
aged from 19 to 46 years old, the overall average 
age – (32.2±1,8) years old. There were 11 men and 9 
women among them, 55% and 45% respectively.
The state of POL and AOS before and after 
treatment was estimated according to the levels 
of malonic aldehyde (MA), superoxide dismutase 
(SOD), SH-groups, catalase and caeruloplasmin.
SOD activity was determined on the basis of 
its ability to compete with nitrotetrazolium blue 
for superoxide anions, which are formed by the 
interaction of the reduced form of aerobic NADN2 
and phenazine methosulfate. The amount of the 
enzyme was determined by spectrometric method. 
The amount of (62.15±2.82) units is considered to be 
the norm.
The level of catalase activity was determined 
by the ability of hydrogen peroxide to form a stable 
colored complex with ammonium molybdate, the 
intensity of the color depends on the catalase activity 
in the sample. The norm of catalase activity in blood 
is (17.48±0.87) %.
The levels of SH-groups, ceruloplasmin and 
MA were determined by Boyer, H.D. Ravin and 
V.N. Orehovych’s methods with tiobarbiturat acid 
respectively. The norm of SH-groups in blood is – 
(60.5±2.13) mmol/L, MA – (2.810±0.085) mcmol/L, 
ceruloplasmin – 300 mg/l.
To evaluate the trophological status before 
and after the treatment of CP in combination with 
SCAD we used the defi nition of such indicators as: 
hemoglobin (Hb), erythrocytes (Er), total protein 
(TP), serum transferrin (TS) and serum ferritin (FS).
Hb level was determined by photometric method, 
the number of Er in the blood – by routine method. 
The norm is considered to be at least 120 g/l for men 
and 110 g/l for women and 4.0 – 5.0×1012/l for men 
and 3.7 – 4.7×1012/l for women respectively. TP in 
blood was determined by the conventional method, 
the norm of which is – 65 – 85 g/l. Normal amounts 
of FS and TS in serum are: 10.0 – 147.0 ng/ml – for 
women and 22.0 – 346.0 ng/ml – for men and 215.0 – 
380.0 mg/dl for women and men respectively.
Statistical signifi cance of differences was assessed 
by averages Mann – Whitney-criteria (p<0.05).
Results and discussion. In the course of studying 
the syndrome indicators of LPO and AOS before 
the treatment, the patients with CP combined with 
SCAD had MA level, as a marker of intensifi cation 
of lipid peroxidation, signifi cantly higher in the I 
and II study groups compared with the control and 
they were respectively (6.35±0.07) mcmol/l and 
(6.39±0,09) mcmol/l. After the treatment MA level 
in I group signifi cantly decreased by 1.40 mcmol/l 
(22.05 %), while in II group this date signifi cantly 
decreased by 2.22 mcmol/l (34.75 %). Such changes 
point to a more signifi cant inhibition of oxidative 
mechanisms under the infl uence of meldonium 
(Vazonat) compared with the results of traditional 
treatment (table 1).
Also, before the treatment we noted a signifi cant 
decrease in enzyme activity of AOS by levels 
of SOD (I group – (39.22±0.47) units, II group 
– (39.27±0.45) units) and SH-groups (I group – 
(38.55±0.47)  mmol/l; II group – (38.52±0.45) mmol/l) 
in both study groups compared to the control. After the 
provided treatment we observed a more considerably 
signifi cant increase of SOD activity (by 24.98 %) 
and the increase of SH-groups (by 15.81 %) in the 
II group, while in the I group, these data increased 
slightly and unreliably.
The level of catalase in serum before the treatment 
in I and II groups of patients was signifi cantly 
higher compared to control ((55.72±1.12) % and 
(55.77±1.03) % respectively). After the treatment, 
this indicator signifi cantly decreased by 16.22 % in 
the I group and by 30.68 % in the II group that again 
proved the antioxidant properties of the drug Vazonat 
(meldonium dihydrate). Regarding the ceruloplasmin 
of blood in the I and II groups, this indicator was 
increased compared to control; after the treatment 
the level of ceruloplasmin in the two study groups 
signifi cantly decreased (by 13.18 % in the I group and 
by 23.48 % in the II group) (Image 1).
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Image 1. Changes indicators of LPO/AOS after treatment 
in patients with CP concomitant with SCAD in two 
comparative groups
Based on the data presented in table 2, we can state 
high effi ciency of the proposed treatment regimen 
that is enhanced by using meldonium compared 
to conventional therapy. TP level in blood after the 
treatment in I group grew by 3.41 g/l – 5.4 %; in II 
group – by 7.90 g/l – 13.8 %, that is by 8.4 % higher 
compared to this indicator in the I group. Also, we 
established a signifi cant increase of Hb level in I 
group from (101.17±1.87) g/l to (107.58±1.28) g/l 
and increase of Er level in blood (8.48 %), while in II 
group there was a signifi cant increase of both the level 
of Hb from (100.64±0.55) g/l to (118.38±1.23) g/l, 
and the level of Er in blood by 19.69 %.
The higher effi ciency of the treatment regimen that 
is enhanced by using meldonium, in patients with CP 
combined with SCAD can also be judged by levels of 
TS and FS. TS level before treatment in I group was – 
(532,22±16,17) g/l, in II group – (527,99±19,72) g/l. 
After the treatment, the indicator fell by 8.71 % in I 
group and by 15.11 % in II group. The improvement 
of FS level in I and II groups (by 17.72 % and by 
35.45 % respectively) was noted, but the growth of 
this indicator in II group was more signifi cant that 
underlines the importance of metabolic therapy in 
patients with comorbidity course of CP and SCAD 
(Image 2).
Image 2. Percentage increase of indicators of trophologi-
cal status in patients with comorbidity of CP and SCAD in 
two comparative groups
Table 1
Status of indicators of LPO/AOS in patients with CP concomitant with SCAD before 






























































* probability of difference regarding to such indicators of control;
** probability of difference regarding to such indicators of their patients with CP+SCAD before treatment;
*** probability of difference regarding to such indicators of patients in I group.
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Conclusions
1) Using metabolic drug Vazonat (meldonium 
dihydrate) in treatment of patients with CP concomitant 
with SCAD contributed to more signifi cant regression 
of prooxidant-antioxidant disturbances in comparison 
with standard conventional therapy.
2) Adding drug Vazonat (meldonium dihydrate) 
to the complex therapy of the patients with comorbid 
course of CP and SCAD contributed to higher 
improvement of indicators of trophological status 
according to the investigated parameters (p<0.05) in 
comparison with the standard basic therapy.
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*** probability of difference regarding to such indicators of patients in I group.
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